詢  價(jià)
                        
                        
                索取COA
                        
                    產(chǎn)品描述
                    產(chǎn)品數(shù)據(jù)庫
                    
                | I. Background | |||||||||||||||||||||||||||||||||||
| 
				 Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials. 
 
 
 
 
 
  | 
		|||||||||||||||||||||||||||||||||||